Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds

NCT07717736 is registered in ClinicalTrials.gov with Abeona Therapeutics, Inc as lead sponsor.

NCT NCT07717736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds
Lead sponsor
Abeona Therapeutics, Inc
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
July 31, 2032
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dystrophic epidermolysis bullosa (deb), epidermolysis bullosa (eb), recessive dystrophic epidermolysis bullosa (rdeb)